Jonathan M. Brotchie

15.5k citations

224 papers · 12.4k indexed · h-index 64

Impact in

Neurology top 0.05%
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
Cellular and Molecular Neuroscience top 0.05%
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Nerve injury and regeneration

Papers in

Neurology 169
- Parkinson's Disease Mechanisms and Treatments 151
- Neurological disorders and treatments 114
Cellular and Molecular Neuroscience 165
- Neuroscience and Neuropharmacology Research 104
- Neurotransmitter Receptor Influence on Behavior 50
- Nerve injury and regeneration 26
- Genetic Neurodegenerative Diseases 14

Co-authors: Susan H. Fox Alan R. Crossman Tom H. Johnston Erwan Bézard Michael P. Hill James B. Koprich Christian E. Gross Philippe Huot
Journals: Movement Disorders (37 papers)Experimental Neurology (24 papers)Journal of Pharmacology and Experimental Therapeutics (11 papers)Neuropharmacology (10 papers)European Journal of Pharmacology (9 papers)
Partner nations: Canada United Kingdom United States

In The Last Decade

Jonathan M. Brotchie

222 papers receiving 12.3k citations

Peers

Countries citing papers authored by Jonathan M. Brotchie

Since Specialization

Citations

This map shows the geographic impact of Jonathan M. Brotchie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan M. Brotchie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan M. Brotchie more than expected).

Fields of papers citing papers by Jonathan M. Brotchie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan M. Brotchie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan M. Brotchie. The network helps show where Jonathan M. Brotchie may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathan M. Brotchie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan M. Brotchie Line = papers co-authored together Jonathan M. Brotchie links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Low β predicts motor output and cell degeneration in the A53T Parkinson’s disease rat model Brain ·柳联勤, 王孟潇, Yael Gherman, R.P. Zimina, Stefan Haufe, Nicoló Gabriele Pozzi, Chiara Palmisano, Ioannis U. Isaias, James B. Koprich, Jonathan M. Brotchie, Andrea A. Kühn, Cordula Matthies, Martin M. Reich, Muthuraman Muthuraman, Jens Volkmann, Chi Wang Ip	2025	1
2	Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease Journal of Neuroinflammation ·Michelle Van Groningen Anthony, Imam Zaky Mubarok, James B. Koprich, Jonathan M. Brotchie, Robert Blum, Jens Volkmann, Chi Wang Ip	2023	22
3	Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease Nature Communications ·P. Venkateswara Reddy, Марина Бондаренко, Janos Groh, Ursula Keber, Fabian Imdahl, C. MİROĞLU, 光広中島, Jingjing Wu, Sawako Tabuchi, Jan Hoffmann, Arun K Dixit, Axel Pagenstecher, Jörg Vogel, Andreas Beilhack, James B. Koprich, Jonathan M. Brotchie, Antoine‐Emmanuel Saliba, Jens Volkmann, Chi Wang Ip	2023	14
4	α-Synuclein–induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms Science Advances ·Wei‐Hua Chiu, C. Rand, Ruth E. Musgrove, Hadar Arien‐Zakay, James B. Koprich, Jonathan M. Brotchie, Rami Yaka, Danny Ben‐Zvi, Menachem Hanani, Jochen Roeper, Joshua A. Goldberg	2021	11
5	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease Cells ·Simoneide Souza Titze-de-Almeida, Cristina Soto‐Sánchez, Eduardo Fernández, James B. Koprich, Jonathan M. Brotchie, Ricardo Titze‐de‐Almeida	2020	65
6	AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease Acta Neuropathologica Communications ·Chi Wang Ip, 田渕恵, Jingchao Liu, Naomi P. Visanji, Jonathan M. Brotchie, Anthony E. Lang, Jens Volkmann, James B. Koprich	2017	118
7	Animal models of α-synucleinopathy for Parkinson disease drug development Nature reviews. Neuroscience ·James B. Koprich, Lorraine V. Kalia, Jonathan M. Brotchie	2017	176
8	Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury Acta Neuropathologica Communications ·Chi Wang Ip, Ioannis U. Isaias, F. T. Cheetham, Dennis Klein, Janos Groh, Aet O’Leary, Susanne Knörr, Takahiro Higuchi, James B. Koprich, Jonathan M. Brotchie, Klaus V. Toyka, Andreas Reif, Jens Volkmann	2016	31
9	l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease Neuropharmacology ·Philippe Huot, Tom H. Johnston, James B. Koprich, Susan H. Fox, Jonathan M. Brotchie	2012	34
10	Synaptic recruitment of AMPA glutamate receptor subunits in levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate Synapse ·Monty Silverdale, Christopher Kobylecki, Penelope J. Hallett, Qin Li, Anthone W. Dunah, Paula Ravenscroft, Erwan Bézard, Jonathan M. Brotchie	2009	54
11	Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice Human Molecular Genetics ·Denis G.M. Jugloff, Katleen Vandamme, Richard F. Logan, Naomi P. Visanji, Jonathan M. Brotchie, James H. Eubanks	2008	77
12	Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease Synapse ·Joohyung Lee, Jordi Gómez-Ramírez, Tom H. Johnston, Naomi P. Visanji, Jonathan M. Brotchie	2008	9
13	Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease Neurobiology of Disease ·Naomi P. Visanji, Susan H. Fox, Tom H. Johnston, Gabriela Reyes, Mark J. Millan, Jonathan M. Brotchie	2008	79
14	Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets Clinical Neuropharmacology ·Michael P. Hill, Jonathan M. Brotchie, Alan R. Crossman, Erwan Bézard, Anne Michel, R. Grimée, Henrik Klitgaard	2004	21
15	Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease Journal of Pharmacology and Experimental Therapeutics ·Michael P. Hill, Paula Ravenscroft, Erwan Bézard, Alan R. Crossman, Jonathan M. Brotchie, Anne Michel, R. Grimée, Henrik Klitgaard	2004	66
16	Levetiracetam (keppra) potentiates the anti-dyskinetic action of amantadine in the MPTP-lesioned marmoset model of Parkinson's disease Journal of Pharmacology and Experimental Therapeutics ·村松淳司, Jonathan M. Brotchie, Anne Michel, Erwan Bézard, Martin Hill, Paula Ravenscroft, R. Grimée, Título da Tese	2003	1
17	Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset Movement Disorders ·Michael P. Hill, Erwan Bézard, Femba Akris Diantoro, Alan R. Crossman, Jonathan M. Brotchie, 朱伯靖, R. Grimée, Henrik Klitgaard	2003	43
18	On the role of endocannabinoids in L-DOPA-induced dyskinesia The Society for Neuroscience Abstracts ·Susan H. Fox, Michael P. Hill, A.R. Crossman, Jonathan M. Brotchie	1999	4
19	Kappa‐opioid receptor agonists increase locomotor activity in the monoamine‐depleted rat model of parkinsonism Movement Disorders ·R.L.J. Magpantay, Alexander T. McKnight, Geoffrey N. Woodruff, Michael P. Hill, Alan R. Crossman, Jonathan M. Brotchie	1998	26
20	Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus European Journal of Pharmacology ·Yannick P. Maneuf, Joanne E. Nash, Alan R. Crossman, Jonathan M. Brotchie	1996	115

About Jonathan M. Brotchie

Jonathan M. Brotchie is a scholar working on Neurology, Cellular and Molecular Neuroscience, Pharmacology, Cognitive Neuroscience and Physiology, having authored 224 papers that have together received 12.4k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (151 papers), Neurological disorders and treatments (114 papers), Neuroscience and Neuropharmacology Research (104 papers), Neurotransmitter Receptor Influence on Behavior (50 papers), Nerve injury and regeneration (26 papers), Cannabis and Cannabinoid Research (21 papers), Autism Spectrum Disorder Research (16 papers) and Genetic Neurodegenerative Diseases (14 papers). The work is most often cited by research in Neurology (7.7k citations), Cellular and Molecular Neuroscience (8.3k citations), Pharmacology (1.9k citations), Cognitive Neuroscience (1.7k citations) and Neurology (705 citations). Jonathan M. Brotchie has collaborated with scholars based in Canada, United Kingdom and United States. Frequent co-authors include Susan H. Fox, Alan R. Crossman, Tom H. Johnston, Erwan Bézard, Michael P. Hill, James B. Koprich, Christian E. Gross, Philippe Huot, Brian Henry and Yannick P. Maneuf. Their work appears in journals such as Movement Disorders, Experimental Neurology, Journal of Pharmacology and Experimental Therapeutics, Neuropharmacology and European Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact